Childhood spinal muscular atrophy

Controversies and challenges

Eugenio Mercuri, Enrico Bertini, Susan T. Iannaccone

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Spinal muscular atrophy is an autosomal recessive disorder characterised by degeneration of motor neurons in the spinal cord and is caused by mutations of the survival of motor neuron 1 gene SMN1. The severity of spinal muscular atrophy is highly variable and no cure is available at present. Consensus has been reached on several aspects of care, the availability of which can have a substantial effect on prognosis, but controversies remain. The development of standards of care for children with the disorder and the identification of promising treatment strategies have changed the natural history of spinal muscular atrophy, and the prospects are good for further improvements in function, quality of life, and survival. A long-term benefit for patients will be the development of effective interventions (such as antisense oligonucleotides), some of which are in clinical trials. The need to be prepared for clinical trials has been the impetus for a remarkable and unprecedented cooperation between clinicians, scientists, industry, government, and volunteer organisations on an international scale.

Original languageEnglish
Pages (from-to)443-452
Number of pages10
JournalThe Lancet Neurology
Volume11
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

Spinal Muscular Atrophies of Childhood
Spinal Muscular Atrophy
Motor Neurons
Clinical Trials
Antisense Oligonucleotides
Standard of Care
Volunteers
Spinal Cord
Industry
Quality of Life
Organizations
Mutation
Survival
Genes
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Childhood spinal muscular atrophy : Controversies and challenges. / Mercuri, Eugenio; Bertini, Enrico; Iannaccone, Susan T.

In: The Lancet Neurology, Vol. 11, No. 5, 05.2012, p. 443-452.

Research output: Contribution to journalArticle

Mercuri, Eugenio ; Bertini, Enrico ; Iannaccone, Susan T. / Childhood spinal muscular atrophy : Controversies and challenges. In: The Lancet Neurology. 2012 ; Vol. 11, No. 5. pp. 443-452.
@article{02d5bd0676e445ce8a7c8988550560e3,
title = "Childhood spinal muscular atrophy: Controversies and challenges",
abstract = "Spinal muscular atrophy is an autosomal recessive disorder characterised by degeneration of motor neurons in the spinal cord and is caused by mutations of the survival of motor neuron 1 gene SMN1. The severity of spinal muscular atrophy is highly variable and no cure is available at present. Consensus has been reached on several aspects of care, the availability of which can have a substantial effect on prognosis, but controversies remain. The development of standards of care for children with the disorder and the identification of promising treatment strategies have changed the natural history of spinal muscular atrophy, and the prospects are good for further improvements in function, quality of life, and survival. A long-term benefit for patients will be the development of effective interventions (such as antisense oligonucleotides), some of which are in clinical trials. The need to be prepared for clinical trials has been the impetus for a remarkable and unprecedented cooperation between clinicians, scientists, industry, government, and volunteer organisations on an international scale.",
author = "Eugenio Mercuri and Enrico Bertini and Iannaccone, {Susan T.}",
year = "2012",
month = "5",
doi = "10.1016/S1474-4422(12)70061-3",
language = "English",
volume = "11",
pages = "443--452",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "5",

}

TY - JOUR

T1 - Childhood spinal muscular atrophy

T2 - Controversies and challenges

AU - Mercuri, Eugenio

AU - Bertini, Enrico

AU - Iannaccone, Susan T.

PY - 2012/5

Y1 - 2012/5

N2 - Spinal muscular atrophy is an autosomal recessive disorder characterised by degeneration of motor neurons in the spinal cord and is caused by mutations of the survival of motor neuron 1 gene SMN1. The severity of spinal muscular atrophy is highly variable and no cure is available at present. Consensus has been reached on several aspects of care, the availability of which can have a substantial effect on prognosis, but controversies remain. The development of standards of care for children with the disorder and the identification of promising treatment strategies have changed the natural history of spinal muscular atrophy, and the prospects are good for further improvements in function, quality of life, and survival. A long-term benefit for patients will be the development of effective interventions (such as antisense oligonucleotides), some of which are in clinical trials. The need to be prepared for clinical trials has been the impetus for a remarkable and unprecedented cooperation between clinicians, scientists, industry, government, and volunteer organisations on an international scale.

AB - Spinal muscular atrophy is an autosomal recessive disorder characterised by degeneration of motor neurons in the spinal cord and is caused by mutations of the survival of motor neuron 1 gene SMN1. The severity of spinal muscular atrophy is highly variable and no cure is available at present. Consensus has been reached on several aspects of care, the availability of which can have a substantial effect on prognosis, but controversies remain. The development of standards of care for children with the disorder and the identification of promising treatment strategies have changed the natural history of spinal muscular atrophy, and the prospects are good for further improvements in function, quality of life, and survival. A long-term benefit for patients will be the development of effective interventions (such as antisense oligonucleotides), some of which are in clinical trials. The need to be prepared for clinical trials has been the impetus for a remarkable and unprecedented cooperation between clinicians, scientists, industry, government, and volunteer organisations on an international scale.

UR - http://www.scopus.com/inward/record.url?scp=84859816485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859816485&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(12)70061-3

DO - 10.1016/S1474-4422(12)70061-3

M3 - Article

VL - 11

SP - 443

EP - 452

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 5

ER -